Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Liver metastases are one of the most common sites of metastasis in advanced gastric cancer.
Chemotherapy remains the mainstay of treatment for these patients, but combination
chemotherapy has encountered a bottleneck in improving patient survival, with no significant
improvement in survival rates at 1, 3 or 5 years. In a previous phase II clinical study we
not only observed the survival benefits of Tislelizumab in the treatment of GI tumors such as
liver, oesophageal and some gastric cancers, but also confirmed the safety of Tislelizumab in
the treatment of advanced GI tumors. This study is a clinical study of PD-1 monoclonal
antibody (Tislelizumab) in combination with SOX (Tegafur + Oxaliplatin) for the treatment of
liver metastases from gastric cancer. It aims to further explore a new combination therapy
for liver metastases from gastric cancer, which is safe and effective for patients with
difficult-to-treat disease.